Management of Dental Patients Taking Anticoagulants or Antiplatelet Drugs



Download 199.67 Kb.
Page8/9
Date conversion17.11.2016
Size199.67 Kb.
1   2   3   4   5   6   7   8   9

Appendix 2. Anticoagulants and Antiplatelet Drugs Available in the UK







UK Trade name(s)

Other names (non-UK)

Oral Anticoagulants







warfarina

Marevan

Coumadin, Jantoven, Uniwarfin,

Aldocumar

(There are another 10-20 trade names used)


phenindione

Dindevan

Phenyline, Pindione

acenocoumarol

Sinthrome

Sintrom, Sinkumar, Syncumar

Oral Antiplatelet Drugs







aspirina

(acetylsalicylic acid, ASA)



Nu-Seals, Microprin, caprin

Dual with dipyridamole: Asasantin Retard, Molita Modified Release



There are numerous brand names for aspirin

clopidogrela

Plavix, Grepid

Iscover

dipyridamole

Persantin, Persantin Retard, Attia Modified Release, Ofcram PR.

Dual with aspirin: Asasantin Retard, Molita Modified Release





prasugrel

Efient

Effient, Prasita

ticagrelor

Brilique

Brilinta, Possia

NOACsb







apixaban

Eliquis



dabigatran

Pradaxa

Pradax, Prazaxa

rivaroxaban

Xarelto




Injectable Anticoagulants







dalteparin

Fragmin

Fragmine, Dalpin, Daltehep

enoxaparin

Clexane

Lovenox, Xaparin, Klexane

tinzaparin

Innohep

Logiparin

a These are currently the most commonly prescribed anticoagulants and antiplatelet drugs

b Also known as DOACs or TSOACs (see Section 1).

Appendix 3. Indications for Anticoagulant or Antiplatelet Therapy


This list is not comprehensive and is intended as a guide to reflect the current use of these drugs in the UK population. Conditions for which the new drugs in particular are licensed are subject to change.

Medical condition

Commonly used treatmentsa

Treatment duration

Notes

Stroke or transient ischaemic attack (TIA) in the absence of atrial fibrillation (AF)

Single or dual antiplatelets

Lifelong

Occasionally warfarin

Stroke prevention in patients with Atrial fibrillation (AF)

Warfarin (other VKAs rarely) or a NOAC

Lifelong

Occasionally single or dual antiplatelets

Thromboembolic disease including, but not limited to Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE)

Warfarin, NOAC or injectable anticoagulant

Treatment usually 6 weeks to 6 months

Prophylaxis can be lifelong



Can be lifelong if there is recurrence or an ongoing untreatable risk factor (e.g. malignancy)

Recent significant surgery

Injectable anticoagulant or NOAC

Usually 2-6 weeks

Occasionally warfarin

Any heart surgery, but especially prosthetic replacement heart valve

Warfarin (or other VKA) or single antiplatelet

Long term


Warfarin or similar for mechanical valves, aspirin for tissue valves

Coronary Heart Disease:

Stable Angina

Unstable Angina

Heart Attack (STEMIb and Non-STEMI)



Single antiplatelet, dual antiplatelet, warfarin, warfarin with single antiplatelet or injectable anticoagulant

Dual therapy for up to 12 months, single aspirin, warfarin or clopidogrel lifelong




Coronary  stent

Single or dual antiplatelets

Dual therapy for up to 12 months, monotherapy lifelong




Kidney dialysis

Heparin or injectable anticoagulants

On day of dialysis




Pregnancy with associated risk factors for venous thromboembolism (VTE)

Aspirin (or injectable anticoagulants in some high risk cases)

Until delivery

Risks include obesity

Treatment of DVT in pregnancy

Injectable anticoagulant

Until at least 6 weeks after delivery




Peripheral Vascular Disease (PVD)/Peripheral Arterial Disease (PAD)

Single or dual antiplatelets

Lifelong




Apical/ventricular/mural thrombus


Warfarin

6 months (reviewed after echocardiography)

Often in combination with dual antiplatelets if recent heart attack

a Further combinations are possible if the patient has multiple indications

b STEMI: ST segment elevation myocardial infarction

1   2   3   4   5   6   7   8   9


The database is protected by copyright ©dentisty.org 2016
send message

    Main page